Home

Vertex Pharmaceuticals (VRTX)

440.12
+0.75 (0.17%)
NASDAQ · Last Trade: May 13th, 2:31 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close439.37
Open437.53
Bid439.81
Ask440.12
Day's Range429.54 - 442.12
52 Week Range377.85 - 519.88
Volume1,700,065
Market Cap114.18B
PE Ratio (TTM)-113.14
EPS (TTM)-3.9
Dividend & YieldN/A (N/A)
1 Month Average Volume1,956,575

Chart

About Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals is a biotechnology company that focuses on discovering, developing, and commercializing innovative therapies to treat serious diseases. With an emphasis on cystic fibrosis, Vertex has pioneered groundbreaking treatments that significantly improve the lives of patients with this genetic disorder. In addition to its work in cystic fibrosis, the company is exploring potential therapies for other rare diseases, including pain management and beta-thalassemia. Vertex is dedicated to advancing scientific research and collaborating with the global medical community to bring new solutions to unmet medical needs. Read More

News & Press Releases

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Todaybenzinga.com
Via Benzinga · May 13, 2025
2 Biotech Stocks That Are Screaming Buys in Mayfool.com
Via The Motley Fool · May 13, 2025
This Stock Just Dropped by 12% in 1 Day. History Says This Will Happen Nextfool.com
Via The Motley Fool · May 13, 2025
S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reforminvestors.com
It's still unclear how President Donald Trump plans to tie drug prices in the U.S. to international prices.
Via Investor's Business Daily · May 12, 2025
Wynn Resorts, Microsoft, Palantir And A Health Care Stock On CNBC's 'Final Trades'benzinga.com
Via Benzinga · May 12, 2025
Prediction: These 2 Stocks Will Outperform the Market in the Next Five Yearsfool.com
Via The Motley Fool · May 12, 2025
Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio?benzinga.com
The worst performing large-cap stocks last week: ARGENX, VRTX, SMMT, MMYT, REGN, RKT, BNTX, AFRM, FNF, LLY, AUR, DASH. Any in your portfolio?
Via Benzinga · May 11, 2025
My Favorite Tariff Safe-Haven Stock to Buy on the Dipfool.com
Via The Motley Fool · May 10, 2025
10 Health Care Stocks With Whale Alerts In Today's Sessionbenzinga.com
Via Benzinga · May 9, 2025
4 No-Brainer Stocks to Buy Right Nowfool.com
Via The Motley Fool · May 9, 2025
Unpacking Q1 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Vertex Pharmaceuticals (NASDAQ:VRTX).
Via StockStory · May 8, 2025
Top S&P500 movers in Wednesday's sessionchartmill.com
Curious about the top performers within the S&P500 index one hour before the close of the markets on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Via Chartmill · May 7, 2025
What's going on in today's session: S&P500 moverschartmill.com
Stay informed about the performance of the S&P500 index in the middle of the day on Wednesday. Uncover the top gainers and losers in today's session for valuable insights.
Via Chartmill · May 7, 2025
Why Vertex Pharmaceuticals Stock Is a Screaming Buy on the Dipfool.com
Via The Motley Fool · May 7, 2025
Market Monitor May 7 ( Hims & Hers Health, Upwork UP - Palantir, Monderna DOWN)chartmill.com
Markets slide on vaccine regulation fears, trade uncertainty, and cautious earnings despite strong tech and consumer stock moves.
Via Chartmill · May 7, 2025
1 S&P 500 Stock with Impressive Fundamentals and 2 to Ignore
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Via StockStory · May 7, 2025
Why Did Vertex Pharmaceuticals Stock Fall On Tuesday?benzinga.com
Vertex posted Q1 EPS and sales below estimates but raised its 2025 revenue outlook, driven by CF drug demand and new product launches in the U.S.
Via Benzinga · May 6, 2025
What's going on in today's session: S&P500 moverschartmill.com
Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session.
Via Chartmill · May 6, 2025
Stocks Fall On Trade Concerns, Oil And Gold Rally: What's Driving Markets Tuesday?benzinga.com
Wall Street edged lower by midday Tuesday as uncertainty surrounding trade policies lingered, with investors adopting a cautious approach ahead of Wednesday’s Federal Reserve meeting.
Via Benzinga · May 6, 2025
Uncover the latest developments among S&P500 stocks in today's session.chartmill.com
Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session.
Via Chartmill · May 6, 2025
Why Vertex Pharmaceuticals Stock Is Sinking Todayfool.com
Via The Motley Fool · May 6, 2025
Which S&P500 stocks are gapping on Tuesday?chartmill.com
Wondering which stocks are making significant price gaps? Explore the S&P500 index on Tuesday to find the gap up and gap down stocks in today's session.
Via Chartmill · May 6, 2025
Vertex Pharmaceuticals Topples 12% On A Series Of First-Quarter Setbacksinvestors.com
The company paused a study of a cystic fibrosis treatment, right on the heels of a scrapped type 1 diabetes program.
Via Investor's Business Daily · May 6, 2025
Rising Costs Weigh on Vertex Q1 Earningsfool.com
Via The Motley Fool · May 6, 2025
Nike To $70? Here Are 10 Top Analyst Forecasts For Tuesdaybenzinga.com
Via Benzinga · May 6, 2025